Skip to content

PET/MRI Artificial Intelligence Reconstruction Algorithm AIR Recon DL Image Quality Evaluation and Clinical Study

PET/MRI Artificial Intelligence Reconstruction Algorithm AIR Recon DL Image Quality Evaluation and Clinical Study

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06856096
Enrollment
65
Registered
2025-03-04
Start date
2025-02-10
Completion date
2027-01-15
Last updated
2025-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Syndrome

Keywords

Artificial Intelligence Reconstruction Algorithms, AIR Recon DL, PET/MRI

Brief summary

PET/MRI artificial intelligence reconstruction algorithm AIR Recon DL image quality evaluation and clinical study

Detailed description

This is a diagnostic pilot study in which 50 patients with disorders of consciousness, Parkinson's syndrome and 15 prostate cancer patients were recruited to undergo PET/MRI imaging to evaluate the impact of AIR Recon DL on scanning and imaging time in different diseases and imaging sites, to determine its efficiency in clinical applications and to analyse its potential advantages in the diagnosis of specific diseases.

Interventions

DIAGNOSTIC_TESTPET/MRI

PET/MR imaging using an integrated TOF PET/MR scanner (Signa, GE Healthcare, WI, USA)

Sponsors

Xijing Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Comparison between different patients

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 1\. Adults between the ages of 18 and 75 who are autonomous; 2. persons with good compliance; 3. those who are mentally alert and able to move around on their own; 4. Those who agree to participate in this clinical trial and sign the informed consent form.

Exclusion criteria

* 1\. Persons who do not have full capacity for civil behaviour; 2. Women during pregnancy and breastfeeding; 3. other implants, prostheses, foreign bodies and patches with electronic implants such as pacemakers, insulin pumps and cochlear implants that are not suitable for MRI; 4. patients with claustrophobia; 5. those who, in the opinion of the investigator, are not suitable for participation in this clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Signal to Noise Ratio1 day from injection of the tracerAn important parameter for measuring image quality, indicating the ratio of signal to noise power
Contrast to Noise Ratio1 day from injection of the tracerDescribes the relative difference in signal strength between the two tissues, the greater the difference the better the image comparison

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026